AI
VRTX $35.50~$38~$35.50 beats by $0.04, guides FY06 revs above consensus Reports Q4 (Dec) loss of $0.20 per share, excluding non-recurring items, $0.04 better than the Reuters Estimates consensus of ($0.24); revenues rose 60.1% year/year to $63.8 mln vs the $56.6 mln consensus. Co issues upside guidance for FY06, sees FY06 revs of $210-235 mln vs. $172.86 mln consensus.
Vertex Pharm tgt raised to $44 from $35 at Credit Suisse (VRTX) 36.11 : Credit Suisse is raising their tgt on VRTX to $44 from $35 based on a more positive VX-950 H.C.V data and clinical advance, expectations for promising VX-702 R.A data in 2Q06, and adjustments to their probability-weighted sum-of-parts, and N.P.V at launch analysis.
Vertex Pharm tgt raised to $44 from $35 at Credit Suisse (VRTX) 36.11 : Credit Suisse is raising their tgt on VRTX to $44 from $35 based on a more positive VX-950 H.C.V data and clinical advance, expectations for promising VX-702 R.A data in 2Q06, and adjustments to their probability-weighted sum-of-parts, and N.P.V at launch analysis.
Know how to make God laugh?
Tell Her your plans ....
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
